Skin Sensitization Testing for New Cosmetic Ingredients: Regulatory Requirements, Methods, and Best

Skin sensitization testing is a core toxicological requirement for the registration and notification of new cosmetic ingredients under China's Cosmetic Supervision and Administration Regulation (CSAR) and comparable international frameworks. This technical article reviews the regulatory basis for sensitization evaluation, the battery of in chemico, in vitro, and in vivo test methods, sample and dossier requirements, and practical strategies for building a compliant safety assessment. Understanding how to select, combine, and interpret sensitization data is essential for regulatory acceptance, consumer safety, and efficient market access.

Technical Overview

Skin sensitization is the immunological process by which repeated exposure to a low-molecular-weight chemical leads to allergic contact dermatitis (ACD), a Type IV delayed hypersensitivity reaction mediated by antigen-specific T lymphocytes. The process involves two distinct phases: induction, in which the immune system is primed after the hapten penetrates the skin and is presented to T cells, and elicitation, in which re-exposure of a sensitized individual triggers an inflammatory response. Because ACD is persistent and effectively incurable once established, demonstrating the absence of sensitization potential is a central safety endpoint for any new cosmetic ingredient.

In China, the Cosmetic Supervision and Administration Regulation (CSAR), effective January 1, 2021, classifies new cosmetic ingredients as either registration-required (higher-risk categories such as preservatives, sunscreen agents, colorants, hair dyes, whitening agents, hair-growth promoters, and other ingredients with higher safety concerns) or notification-based. Skin sensitization data is a mandatory component of the toxicological dossier for registered ingredients and is frequently required for notified ingredients depending on exposure scenario and chemical characteristics. Test methods must comply with the Safety and Technical Standards for Cosmetics (2015 Edition) or be internationally recognized, scientifically validated methods accompanied by adequate justification.

The biological mechanism of skin sensitization is described by the OECD adverse outcome pathway (AOP), which identifies four key events: (1) covalent binding of electrophilic substances to skin proteins, (2) activation of keratinocytes including ARE-Nrf2-dependent gene expression, (3) activation of dendritic cells with upregulation of surface markers and cytokines, and (4) proliferation and activation of antigen-specific T cells. Each key event corresponds to validated test methods, enabling a mechanistically coherent, tiered testing strategy consistent with the 3Rs principle of replacing, reducing, and refining animal use.

Testing Samples

The test item should originate from a representative commercial-scale or pilot batch and be fully characterized before testing. A certificate of analysis, safety data sheet, manufacturing process description, impurity profile, proposed formulation concentration, and stability information should accompany the sample. Typical sample requirements are summarized below.

Pure Synthetic and Natural Chemical Ingredients

Single-chemical ingredients are tested at the highest technically achievable purity, generally with a defined CAS number, molecular structure, and impurity profile. Solid and liquid materials are accepted, and solubility in standard vehicles is verified during method suitability screening. Approximately 5 to 10 grams are sufficient for the in chemico and in vitro test battery, while the local lymph node assay typically requires 25 grams or more.

Botanical Extracts and Natural Complexes

Plant extracts and other multi-constituent natural substances present analytical challenges, including batch-to-batch variability, intrinsic coloration, and precipitation that may interfere with peptide-based or fluorescence-based readouts. These materials are normally tested in the marketed concentrate form, with the carrier solvent system documented. Known sensitizing constituents, such as certain terpenes and quinone precursors, must be quantified and considered in the overall assessment.

Biotechnology-Derived Ingredients

Fermentation products, enzymatically modified materials, recombinant peptides, and other biotechnology-derived ingredients require attention to molecular size, protein content, endotoxin load, and solubility in culture media. Large or proteinaceous molecules may fall outside the applicability domain of peptide reactivity assays, in which case cell-based or in vivo confirmation may be necessary.

Polymers, Preservatives, and Functional Additives

High-molecular-weight polymers with limited solubility may require adapted solvent systems or scientific justification for method modifications. Preservatives and other intentionally bioactive additives are subject to heightened regulatory scrutiny and generally require the most complete sensitization dataset, since their antimicrobial or functional activity increases the plausibility of biological interaction.

• Recommended sample logistics: triple-container packaging, tamper-evident seals, batch traceability, and documented storage conditions (temperature, light, humidity).
• Common vehicles: acetone and olive oil (4:1) for the local lymph node assay; distilled water, ethanol, or dimethyl sulfoxide dilutions for cell-based assays; buffered media for peptide reactivity testing.
• Preliminary compatibility testing is performed to confirm that the test item does not interfere with analytical detection, precipitate in culture, or produce nonspecific cytotoxicity.

Testing Items

The sensitization test program for a new cosmetic ingredient typically comprises the following items, selected according to the physicochemical properties of the material and the target regulatory framework.

• Hazard identification: classification of the ingredient as a skin sensitizer or non-sensitizer based on validated predictive assays.
• Dose-response characterization: determination of threshold parameters such as the EC3 value in the local lymph node assay, the CV75 cytotoxicity value in dendritic cell assays, and mean peptide depletion percentages in reactivity assays.
• Potency categorization: assignment of UN GHS Category 1A (strong sensitizer) or Category 1B (other sensitizers) where required for classification and labeling.
• Keratinocyte pathway activation: quantification of ARE-Nrf2-mediated luciferase induction, including the EC1.5 concentration and maximal induction fold.
• Dendritic cell activation: measurement of CD86 and CD54 surface marker induction relative to isotype and solvent controls.
• Supporting endpoints: preliminary irritation and cytotoxicity testing for dose selection, physicochemical compatibility screening, and consideration of photosensitization potential for ultraviolet-absorbing ingredients.

Testing Methods

Testing is performed by GLP-compliant or accredited third-party laboratories using internationally validated methods. The current method hierarchy reflects the OECD AOP for skin sensitization.

In Chemico Peptide Reactivity (OECD TG 442C)

The direct peptide reactivity assay (DPRA) quantifies the depletion of synthetic cysteine- and lysine-containing peptides after exposure to the test chemical, analyzed by HPLC with UV detection at 220 nanometers. Mean peptide depletion below 6.38 percent indicates minimal reactivity, with higher thresholds defining low, moderate, and high reactivity classes. The assay addresses the molecular initiating event of the AOP and is suitable as the first step of most integrated strategies.

In Vitro Keratinocyte Activation (OECD TG 442D)

ARE-Nrf2 luciferase reporter methods, such as KeratinoSens and LuSens, use immortalized human keratinocyte cell lines carrying a luciferase gene under control of the antioxidant response element. Concentration-dependent luciferase induction of 1.5-fold or greater at non-cytotoxic concentrations indicates keratinocyte activation, the second key event of the AOP.

In Vitro Dendritic Cell Activation (OECD TG 442E)

The human cell line activation test (h-CLAT) measures CD86 and CD54 expression in THP-1 monocytic cells, while the U-SENS assay measures CD86 induction in U937 cells. Both methods include a cytotoxicity range-finding step to establish the CV75 concentration, and results are expressed as relative fluorescence intensity against controls. These assays address the third key event of the AOP.

In Vivo Local Lymph Node Assay (OECD TG 429 and Variants)

The local lymph node assay applies the test substance to the ears of mice for three consecutive days, followed by measurement of lymphocyte proliferation in the draining auricular lymph nodes. A stimulation index of 3 or greater identifies a sensitizer, and the interpolated EC3 value supports potency classification, with EC3 values at or below 2 percent generally corresponding to Category 1A. Non-radioactive variants, such as the LLNA: BrdU-ELISA covered under OECD TG 442A/442B, reduce animal burden while retaining performance.

In Vivo Guinea Pig Methods (OECD TG 406)

The guinea pig maximization test of Magnusson and Kligman and the Buehler occluded patch test remain available where the LLNA is technically unsuitable, for example for certain complex or poorly soluble materials. These assays use intradermal or epicutaneous induction followed by challenge exposure, with erythema and edema scored according to standardized grading schemes.

Human Confirmatory Testing

Human repeat insult patch testing (HRIPT) may be conducted as a supplementary, ethically reviewed confirmation step after predictive hazard assessment, typically under institutional review and informed consent. Human data alone is generally not accepted as the primary basis for hazard identification of a new ingredient but can support overall weight-of-evidence conclusions.

Integrated and Defined Approaches

OECD Test Guideline 497 establishes defined approaches, including the widely used "2 out of 3" strategy combining DPRA, an ARE-Nrf2 luciferase assay, and h-CLAT. When at least two of the three component methods yield concordant results, a prediction of sensitizer or non-sensitizer status, and in some strategies potency class, can be assigned without animal testing. Read-across from structurally related analogues and (Q)SAR predictions, for example using the OECD QSAR Toolbox, complement the testing strategy within a documented weight-of-evidence framework.

Applications

Sensitization testing data for new cosmetic ingredients supports multiple regulatory and commercial objectives across global markets.

• NMPA registration and notification dossiers for new cosmetic ingredients under the CSAR framework, including subsequent annual safety monitoring reports.
• Cosmetic product safety assessments, including EU-style product safety reports prepared by qualified safety assessors.
• Chemical registration programs such as REACH, where sensitization is a standard tonnage-band endpoint relevant to cosmetic-grade substances.
• GHS and CLP classification, hazard communication, and safety data sheet development for ingredient manufacturers and distributors.
• Derivation of safe concentration limits and no-expected-sensitization-induction levels (NESIL) for quantitative risk assessment.
• Research and development screening to deprioritize candidate ingredients early and to support reformulation after a regulatory or market-driven safety signal.
• Occupational exposure assessment for manufacturing and filling operations involving sensitizing raw materials.

FAQ

Is animal testing mandatory for sensitization assessment of new cosmetic ingredients in China?

No single in vivo test is automatically mandatory. Regulators prioritize validated alternative methods consistent with the 3Rs principle, provided the methods are incorporated into recognized standards or are accompanied by scientific justification. In vivo studies remain available when non-animal methods are outside their applicability domain, when results are inconclusive, or when confirmatory data is needed for a weight-of-evidence conclusion.

What is the "2 out of 3" defined approach?

It is an OECD TG 497 strategy that combines DPRA, an ARE-Nrf2 luciferase keratinocyte assay, and h-CLAT. When at least two of the three methods agree, the concordant outcome is used to assign sensitizer or non-sensitizer status, and certain variants of the approach also support potency categorization, all without animal use.

How much sample is required for a full sensitization test battery?

As a general guideline, 5 to 10 grams are sufficient for the in chemico and in vitro battery, 25 grams or more for the local lymph node assay, and approximately 50 grams for guinea pig studies, allowing for repeat tests and retention samples. Exact quantities depend on solubility, required concentrations, and laboratory-specific protocols.

Can existing data, read-across, or computational models replace new testing?

Yes, within a documented weight-of-evidence framework. High-quality historical studies from accredited third-party laboratories conducted under GLP, read-across from structurally similar analogues with supporting toxicokinetic rationale, and (Q)SAR predictions can reduce or replace experimental testing, subject to regulator acceptance of the technical documentation.

What is the EC3 value and why does it matter?

The EC3 value is the estimated concentration of test substance that produces a stimulation index of 3 in the local lymph node assay. It serves as a quantitative induction threshold used for potency classification, with EC3 values at or below 2 percent generally indicating strong sensitizers, and it can be extrapolated to derive safe human exposure levels in quantitative risk assessment.

Do botanical extracts require sensitization testing?

New botanical ingredients generally require a sensitization assessment, although the approach may be tailored. Testing is usually performed on the marketed concentrate, with attention to assay interference from color and precipitation, while known sensitizing constituents and data from related species inform read-across arguments within the overall weight of evidence.

What are typical turnaround times for each method?

The DPRA typically requires 2 to 3 weeks, ARE-Nrf2 and dendritic cell assays approximately 4 to 6 weeks including cytotoxicity range-finding, the local lymph node assay approximately 6 to 8 weeks, and guinea pig maximization studies approximately 10 to 12 weeks. Integrated dossier preparation, including quality review and report compilation, should be planned in addition to these laboratory timelines.